牛乳杆菌 (Lactobacillus delbrueckii) 的一个亚种 乳糖 CKDB001 通过代谢调制改善斯科波胺诱导的认知障碍
Hyerim Kim1, Hyun Kim2, Yeonmi Lee1
1Genome and Company, Suwon 16229, Republic of Korea.
International journal of molecular sciences
|December 30, 2025
概括
乳杆菌delbrueckii CKDB001通过调节肠道代谢物和大脑通路来改善记忆力,类似于donepezil. 这种益生菌为认知障碍提供了潜在的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 微生物学 微生物学
- 代谢学 代谢学 代谢学
背景情况:
- 微生物组代谢物是肠-大脑轴的关键,影响认知和神经保护.
- 斯科波胺是一种已知诱导记忆障碍的诱导剂.
研究的目的:
- 调查Lactobacillus delbrueckii CKDB001是否可以通过代谢调节缓解斯科波拉胺诱导的记忆障碍.
- 将CKDB001的疗效与donepezil进行比较.
主要方法:
- ICR小鼠接受了CKDB001或donepezil的治疗.
- 评估包括行为测试,微生物组分析,代谢学和分子分析.
- 关键的分子标包括陶酸化,GSK-3信号传递,肠道紧接点和乙胆酶活性.
主要成果:
- CKDB001剂量依赖地改善了空间工作记忆,与donepezil相比.
- 这两种疗法都调节了肠道微生物群,并增加了托衍生的醇代谢产物.
- CKDB001显示出更明显的代谢效应和更好的恢复乙胆酶活性.
结论:
- CKDB001通过协调微生物,代谢和神经元路径来缓解认知缺陷.
- 这种益生菌是一种基于微生物的治疗方法,用于治疗认知障碍.
- CKDB001可能会提供与多尼佩西尔 (donepezil) 相似的好处,但潜在限制较少.
更多相关视频
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
10.2K
04:06Author Spotlight: Challenges in Developing Dry Eye Animal Models and Future Research Directions
Published on: February 9, 2024
2.7K
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
496
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
496
Alzheimer's Disease: Treatment
736
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
736
